Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced/recurrent ovarian and uterine cancers

出版年份 2019 全文链接

标题

作者

关键词

Atezolizumab, Immune checkpoint inhibitor, PD-L1, Epithelial ovarian cancer, Uterine cancer, Molecular markers

出版物

GYNECOLOGIC ONCOLOGY

Volume 154, Issue 2, Pages 314-322

出版商

Elsevier BV

发表日期

2019-06-14

DOI

10.1016/j.ygyno.2019.05.021

向作者/读者发起求助以获取更多资源

Protocol

在线求助

Reagent

在线求助

Reprint

联系作者

Publish scientific posters with Peeref

Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.

Learn More

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started